Sutro Biopharma Inc. Common Stock
STROUnited States
5 filed reports · 198 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
5 reports · Jun 2025 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 4 | 776 | Jun 2025 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 1 | 512 | Dec 2025 |
Financial data
198 concepts · 1,288 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial198 concepts · 1,288 facts · Mar 2024 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value12 · Mar 2024 to Jun 2026
- Net income loss12 · Mar 2024 to Jun 2026
- Other comprehensive income loss available for sale securities adjustment net of tax12 · Mar 2024 to Jun 2026
- Stockholders equity (US GAAP)12 · Mar 2024 to Jun 2026
- Adjustments related to tax withholding for share based compensation11 · Mar 2024 to Mar 2026
- Allocated share based compensation expense11 · Jun 2024 to Jun 2026
- Cash and cash equivalents at carrying value11 · Jun 2024 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents11 · Jun 2024 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents including disposal group and discontinued operations11 · Jun 2024 to Jun 2026
- Comprehensive income net of tax11 · Jun 2024 to Jun 2026
- General and administrative expense (US GAAP)11 · Jun 2024 to Jun 2026
- Income tax expense benefit11 · Jun 2024 to Jun 2026
- Interest and other income (expense), net11 · Jun 2024 to Jun 2026
- Investment income nonoperating11 · Jun 2024 to Jun 2026
- Lease cost11 · Jun 2024 to Jun 2026
- Non-cash interest expense on deferred royalty obligation11 · Jun 2024 to Jun 2026
- Non-cash interest expense related to the sale of future royalties11 · Jun 2024 to Jun 2026
- Operating expenses (US GAAP)11 · Jun 2024 to Jun 2026
- Operating income loss11 · Jun 2024 to Jun 2026
- Operating lease cost11 · Jun 2024 to Jun 2026
- Operating lease expense11 · Jun 2024 to Jun 2026
- Research and development expense11 · Jun 2024 to Jun 2026
- Restricted cash noncurrent11 · Jun 2024 to Jun 2026
- Revenue11 · Jun 2024 to Jun 2026
Segments
Figures broken down by business line, region, product or another axis the company reports on.
No segment breakdowns.
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.